Skip to main content
Book cover

Bone Metastases from Prostate Cancer pp 135–146Cite as

Combinations of Hormonal Therapy and Chemotherapy

  • 1279 Accesses

Abstract

Prostate cancer (PC) is a heterogeneous disease, with a complex natural history, whose growth is driven by androgens and androgen receptors. In most cases, patients have localized disease at presentation, which may be successfully treated with radical prostatectomy and external beam radiation. However, many patients subsequently develop metastatic disease. De novo metastases can also occur in a minority of cases.Androgen deprivation therapy (ADT) is the standard treatment of metastatic hormone-naïve (or castration-sensitive) prostatic cancer (CSPC). ADT usually determines a profound PSA decline and a radiological and clinical benefit in most patients. However, essentially all patients experience progression to castration-resistant prostate cancer (CRPC) despite persisting low testosterone levels in around 1–2 years, and overall prognosis remains disappointing, although subsequent active treatments are available. Early targeting of cells that survive hormonal therapy may potentially prevent the development of CRPC. The aim of these therapeutic strategies is the elimination of resistant cells at the time the tumor is apparently “androgen sensitive”. The large randomized studies analyzed in this chapter, addressing the early use of docetaxel in combination with ADT in men with metastatic CSPC, have shown evidence that at least a subset of patients with metastatic CSPC may benefit from the combination of ADT with docetaxel as initial therapy.

Keywords

  • Prostate Cancer
  • Androgen Receptor
  • Zoledronic Acid
  • Metastatic Prostate Cancer
  • Abiraterone Acetate

These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

This is a preview of subscription content, access via your institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-3-319-42327-2_12
  • Chapter length: 12 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   109.00
Price excludes VAT (USA)
  • ISBN: 978-3-319-42327-2
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Softcover Book
USD   149.99
Price excludes VAT (USA)
Hardcover Book
USD   149.99
Price excludes VAT (USA)
Learn about institutional subscriptions
Fig. 12.1

References

  1. Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016.CA. Cancer J Clin 66:7–30

    CrossRef  Google Scholar 

  2. Ferlay J, Shin HR, Bray F et al (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917

    CAS  CrossRef  PubMed  Google Scholar 

  3. Gundem G, Van Loo P, Kremeyer B et al (2015) The evolutionary history of lethal metastatic prostate cancer. Nature 520:353–357

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  4. Attard G, Parker C, Eeles RA et al (2016) Prostate cancer. Lancet 387:70–82

    CrossRef  PubMed  Google Scholar 

  5. Wu JN, Fish KM, Evans CP et al (2014) No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer 120:818–823

    CAS  CrossRef  PubMed  Google Scholar 

  6. Miller DC, Hazer KS, Stewart A et al (2003) Prostate carcinoma presentation, diagnosis and staging: an update from the National Cancer Data Base. Cancer 98:1169–1178

    CrossRef  PubMed  Google Scholar 

  7. Ryan CJ, Elkin EP, Small EJ et al (2006) Reduced incidence of bony metastasis at initial prostate cancer diagnosis: data from CaPSURE. Urol Oncol 24:396–402

    CrossRef  PubMed  Google Scholar 

  8. Center MM, Jemal A, Lortet-Tieulent J et al (2012) International variation in prostate cancer incidence and mortality rates. Eur Urol 61:1079–1092

    CrossRef  PubMed  Google Scholar 

  9. Wilt TJ, Brawer MK, Jones KM et al (2012) Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 367:203–213

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  10. Wallis CJ, Saskin R, Choo R et al (2015) Surgery versus radiotherapy for clinically localized prostate cancer: a systematic review and meta-analysis. Eur Urol 70(1):21–30

    Google Scholar 

  11. Huggins C, Hodges CV (1941) Studies in prostate cancer. 1. The effect of castration of oestrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293–297

    CAS  Google Scholar 

  12. Gillessen S, Omlin A, Attard G et al (2016) Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol 26:1589–1604

    Google Scholar 

  13. D’Angelillo RM, Franco P, De Bari B et al (2015) Combination of androgen deprivation therapy and radiotherapy for localized prostate cancer in the contemporary era. Crit Rev Oncol Hematol 93:136–148

    CrossRef  PubMed  Google Scholar 

  14. Hussain M, Tangen C, Higano C et al (2016) Evaluating intermittent androgen-deprivation therapy phase III clinical trials: the devil is in the details. J Clin Oncol 34:180–185

    CrossRef  CAS  Google Scholar 

  15. Magnan S, Zarychanski R, Pilote L et al (2015) Intermittent vs continuous androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. JAMA Oncol 1:1261–1269

    CrossRef  PubMed  Google Scholar 

  16. Prostate Cancer Trialists’ Collaborative Group (2000) Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 355:1491–1498

    Google Scholar 

  17. Samson DJ, Seidenfeld J, Schmitt B et al (2002) Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 95:361–376

    CAS  CrossRef  PubMed  Google Scholar 

  18. James ND, Spears MR, Clark NW et al (2015) Survival with newly diagnosed metastatic prostate cancer in the “Docetaxel Era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). Eur Urol 67:1028–1038

    CrossRef  PubMed  Google Scholar 

  19. Zong Y, Goldstein AS (2013) Adaptation or selection: mechanisms of castration-resistant prostate cancer. Nat Rev Urol 10:90–98

    CAS  CrossRef  PubMed  Google Scholar 

  20. Ahmed M, Li LC (2013) Adaptation and clonal selection models of castration-resistant prostate cancer: current perspective. Int J Urol 20:362–371

    CrossRef  PubMed  Google Scholar 

  21. Goldstein AS, Stoyanova T, Witte ON (2010) Primitive origins of prostate cancer: in vivo evidence for prostate-regenerating cells and prostate cancer-initiating cells. Mol Oncol 4:385–396

    CrossRef  PubMed  PubMed Central  Google Scholar 

  22. Eigl BJ, Eggener SE, Baybik J et al (2005) Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clin Cancer Res 11:4905–4911

    CAS  CrossRef  PubMed  Google Scholar 

  23. Tang Y, Khan MA, Goloubeva O et al (2006) Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice. Clin Cancer Res 12:169–174

    CAS  CrossRef  PubMed  Google Scholar 

  24. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512

    CAS  CrossRef  PubMed  Google Scholar 

  25. Petrylak DP, Tangen CM, Hussain MHA et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520

    CAS  CrossRef  PubMed  Google Scholar 

  26. de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147–1154

    CrossRef  CAS  PubMed  Google Scholar 

  27. Zhu ML, Horbinski CM, Garzotto M et al (2010) Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res 70:7992–8002

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  28. De Reijke TM, Keuppens FL, Whelan P et al (1999) Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patient with poor prognosis: the final results of a European Organization for Research in Cancer Therapy Genitourinary Group Trial. J Urol 162:1658–1664

    CrossRef  PubMed  Google Scholar 

  29. Janknegt RA, Boon TA, van de Beek C, Grob P (1997) Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: a randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. The Dutch Estracyt Study Group. Urology 49:411–420

    CAS  CrossRef  PubMed  Google Scholar 

  30. Noguchi M, Noda S, Yoshida M et al (2004) Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. Int J Urol 11:103–109

    CAS  CrossRef  PubMed  Google Scholar 

  31. Millikan RE, Wen S, Pagliaro LC et al (2008) Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J Clin Oncol 26:5936–5942

    CrossRef  PubMed  PubMed Central  Google Scholar 

  32. Pummer K, Lehnert M, Stettner H, Hubmer G (1997) Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur Urol 32:81–85

    CAS  PubMed  Google Scholar 

  33. Gravis G, Fizazi K, Joly F et al (2013) Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 14:149–158

    CAS  CrossRef  PubMed  Google Scholar 

  34. Gravis G, Boher J-M, Joly F et al (2016) Androgen deprivation therapy (ADT) plus docetaxel versus ADT alone for hormone-naïve metastatic prostate cancer: long-term analysis of the GETUG-AFU-15 phase III trial. Eur Urol 70(1):21–30

    Google Scholar 

  35. Sweeney CJ, Chen YH, Carducci M et al (2015) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 373:737–746

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  36. James ND, Sydes MR, Clarke NW et al (2008) STAMPEDE: systemic therapy for advancing or metastatic prostate cancer. A Multi-arm multi-Stage randomised controlled trial. Clin Oncol 20:577–581

    CAS  CrossRef  Google Scholar 

  37. James ND, Sydes MR, Clarke NW et al (2016) Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage platform randomized controlled trial. Lancet 387:1163–1177

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  38. Glass TR, Tangen CM, Crawford ED, Thompson I (2003) Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol 169:164–169

    CAS  CrossRef  PubMed  Google Scholar 

  39. James ND, Sydes MR, Mason MD et al (2012) Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomized controlled trial. Lancet Oncol 13:549–558

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  40. Sydes MR, Parmar MK, Mason MD et al (2012) Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial. Trials 13:168

    CrossRef  PubMed  PubMed Central  Google Scholar 

  41. Attard G, Sydes MR, Mason MD et al (2014) Combining enzalutamide with abiraterone, prednisone, and androgen deprivation therapy in the STAMPEDE trial. Eur Urol 66:799–802

    CAS  CrossRef  PubMed  Google Scholar 

  42. Tucci M, Bertaglia V, Vignani F et al (2016) Addition of docetaxel to androgen deprivation therapy for patients with hormone-sensitive metastatic prostate cancer: a systematic review and meta-analysis. Eur Urol 69:563–573

    CAS  CrossRef  PubMed  Google Scholar 

  43. Vale CL, Burdett S, Rydzewska LHM et al (2016) Addition of docetaxel or bisphosphonates to standard of care in men with localized or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol 17:243–256

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  44. Fizazi K, Faivre L, Lesaunier F et al (2015) Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localized prostate cancer (GETUG 12): a phase 3 randomised controlled trial. Lancet Oncol 16:787–794

    CAS  CrossRef  PubMed  Google Scholar 

  45. Halabi S, Lin CY, Kelly WK et al (2014) Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol 32:671–677

    CrossRef  PubMed  PubMed Central  Google Scholar 

  46. Halabi S, Kelly WK, Ma H et al (2016) Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer. J Clin Oncol 34:1652–1659

    CrossRef  PubMed  Google Scholar 

  47. Gravis G, Boher JM, Fizazi K et al (2015) Prognostic factors for survival in non-castrate metastatic prostate cancer: validation of the Glass model and development of a novel simplified prognostic model. Eur Urol 68:196–204

    CrossRef  PubMed  Google Scholar 

  48. Fizazi K, Jenkins C, Tannock IF (2015) Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra. Ann Oncol 26:1660–1667

    CAS  CrossRef  PubMed  PubMed Central  Google Scholar 

  49. Franke RM, Carducci MA, Rudek MA, et al (2010) Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. J Clin Oncol 28:4562–4567

    Google Scholar 

  50. Templeton AJ, Vera-Badillo FE, Wang L, et al (2013) Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials. Ann Oncol 24:2972–2977

    Google Scholar 

  51. Fizazi K, Abrahamsson P-A, Ahlgren G, et al (2015) Achievements and perspectives in prostate cancer phase 3 trials from Genitourinary Research Groups in Europe: introducing the Prostate Cancer Consortium in Europe. Eur Urol 67:904–912

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Cliniche Humanitas Gavazzeni, Bergamo, Italy

    Giovanni Luca Ceresoli, Maria Bonomi & Maria Grazia Sauta

  2. Academic Unit of Medical Oncology, IRCCS AOU San Martino-IST (San Martino University Hospital and National Cancer Research Institute), Genoa, Italy

    Elisa Zanardi & Francesco Boccardo

Authors
  1. Giovanni Luca Ceresoli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maria Bonomi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maria Grazia Sauta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elisa Zanardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Francesco Boccardo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giovanni Luca Ceresoli .

Editor information

Editors and Affiliations

  1. University of Verona, Director of Metabolic Bone Diseases and Osteoncology Unit, Internal Medicine Department of Medicine, Verona, Italy

    Francesco Bertoldo

  2. IRCCS AOU San Martino-IST National Cancer Research Institute, Department of Internal Medicine and Medical specialties (DIMI), School of Medical and Pharmacological Sciences, University of Genoa, Academic Unit of Medical Oncology, Department of Oncology (DIPOE), Genoa, Italy

    Francesco Boccardo

  3. Humanitas Gavazzeni Clinic, Clical Scientific Director Department of Nuclear Medicine, Bergamo, Italy

    Emilio Bombardieri

  4. Veneto Institute of Oncology IOV - IRCCS, Nuclear Medicine and Molecular imaging Unit, Padova, Italy

    Laura Evangelista

  5. Radiation Oncology 1 and Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Oncology and Hemato-oncology, Università di Milano, Milan, Italy

    Riccardo Valdagni

Rights and permissions

Reprints and Permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Ceresoli, G.L., Bonomi, M., Sauta, M.G., Zanardi, E., Boccardo, F. (2017). Combinations of Hormonal Therapy and Chemotherapy. In: Bertoldo, F., Boccardo, F., Bombardieri, E., Evangelista, L., Valdagni, R. (eds) Bone Metastases from Prostate Cancer . Springer, Cham. https://doi.org/10.1007/978-3-319-42327-2_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-42327-2_12

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-42326-5

  • Online ISBN: 978-3-319-42327-2

  • eBook Packages: MedicineMedicine (R0)